Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 12/20 | 0.74 |
| ▸ | ESR2 | Q92731 | 12/20 | 0.74 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.64 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.63 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.56 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.56 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.56 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | CETP | P11597 | 4/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8740097 | 0.88 | ESR1 (0.74) | ESR1ESR2HDAC6APP | |
| SCHEMBL27090233 | 0.87 | ESR1 (0.96) | ESR1ESR2PIK3CAPIK3CBHSPD1 | |
| SCHEMBL4476460 | 0.86 | ESR1 (1.00) | ESR1ESR2PIK3CAPIK3CBHDAC6 | |
| SCHEMBL12726617 | 0.82 | SMN1; SMN2 (0.74) | HDAC6HSPD1PTPN2PTPN1PTPN5 | |
| SCHEMBL2427880 | 0.82 | HDAC6 (0.63) | ESR1ESR2HDAC6HSPD1PTPN2 | |
| SCHEMBL946252 | 0.81 | HDAC6 (0.76) | HDAC6HSPD1PTPN2PTPN1PTPN5 | |
| SCHEMBL18726303 | 0.80 | ESR1 (0.81) | ESR1ESR2PIK3CAPIK3CBAPP | |
| SCHEMBL4032655 | 0.80 | ESR1 (0.81) | ESR1ESR2PIK3CAPIK3CBHSPD1 | |
| SCHEMBL5901662 | 0.80 | ESR1 (0.81) | ESR1ESR2PIK3CAPIK3CBHDAC6 | |
| SCHEMBL1733840 | 0.79 | HDAC6 (0.60) | ESR1ESR2HDAC6HSPD1PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371777-B2 | Cyclic compound and PPAR agonist | EISAI CO., LTD. (JP) | 2008-05-13 | — | — | US | disclosed |
| US-20050244718-A1 | Polymerizable, luminescent compounds and mixtures, luminescent polymer materials and their use | MERCK PATENT GMBH (DE) | 2005-11-03 | — | — | US | disclosed |
| EP-1517974-A1 | POLYMERIZABLE, LUMINESCENT COMPOUNDS AND MIXTURES, LUMINESCENT POLYMER MATERIALS AND THEIR USE | MERCK PATENT GmbH (DE) | 2005-03-30 | — | — | EP | disclosed |
| US-20050014833-A1 | Cyclic compound and ppar agonist | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1452521-A1 | CYCLIC COMPOUND AND PPAR AGONIST | Eisai Co., Ltd. (JP) | 2004-09-01 | — | — | EP | disclosed |
| WO-2004003103-A1 | POLYMERIZABLE, LUMINESCENT COMPOUNDS AND MIXTURES, LUMINESCENT POLYMER MATERIALS AND THEIR USE | MERCK PATENT GMBH (DE) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014833-A1 | Cyclic compound and ppar agonist | PPARA, PPARG, PPARD | ESR1 132/4885ESR2 98/4885PIK3CA 2365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.